All In Biotech

Drug Trial Radar · NCT01043393

Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study

An Open Label, Safety/Efficacy Study to Assess the Potential for Adrenal Suppression Following Multiple Dosing With Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Jun 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Feb 2010

Primary completion

Jun 2010

Study completion Jun 2010

Sponsor

Sponsor type
Industry
First posted
Jan 6, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the potential of desoximetasone 0.25% topical spray to suppress HPA axis function. The potential for adrenal suppression will be assessed following multiple dosing with Desoximetasone 0.25% Topical Spray in patients with moderate to severe plaque psoriasis. The secondary objectives are to evaluate the efficacy parameters and to evaluate the adverse event (AE) profile.

Conditions

  • Psoriasis

Interventions

  • Desoximetasone 0.25% sprayDrug

    Desoximetasone spray applied to affected areas twice daily for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients in the Study With Hypothalamic Pituitary Adrenal (HPA) Axis SuppressionTime frame: 28 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Investigator Site

    Hot Springs, Arkansas

  • Investigator Site

    Albuquerque, New Mexico

  • Investigator Site

    Simpsonville, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.